Intranasal amphiphile-protein conjugate vaccine
Invention type: Technology
/
Case number: #23991H
What is disclosed is a vaccine comprising an immunogen conjugated to an albumin-binding polymer-lipid tail, wherein the vaccine is suitable for transmucosal (e.g, intranasal) administration. Also disclosed is a method of using the vaccine to immunize a subject by transmucosal (e.g, intranasal) administration of an effective amount of the vaccine, alone or with an adjuvant.
Researchers
Darrell J Irvine
/
Brittany Hartwell
Technology Areas: Chemicals & Materials: Polymers / Therapeutics: Proteins & Antibodies, Vaccines
Impact Areas: Healthy Living
-
intranasal amphiphile-protein conjugate vaccine
Japan | Published application -
transmucosal amphiphile-protein conjugate vaccine
United States of America | Published application -
transmucosal amphiphile-protein conjugate vaccine
European Patent Convention | Published application
License this technology
Interested in this technology? Connect with our experienced licensing team to initiate the process.
Sign up for technology updates
Sign up now to receive the latest updates on cutting-edge technologies and innovations.